

Anti-IL-17 & IL-17F & Serum Albumin Reference Antibody (Sonelokimab)

Catalog # APR11558

Product Information


Application	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	Q16552 & Q96PD4 & P02768
Reactivity	Human
Clonality	Bispecific
Isotype	VHH-VHH-VHH

Additional Information


Target/Specificity	IL-17 / IL-17A / CTLA-8,IL-17F,Serum Albumin / SA / HSA
Expression system	CHO

Protein Information

Images




Anti-IL-17 & IL-17F & Serum Albumin Reference Antibody (Sonelokimab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.




The purity of Anti-IL-17 & IL-17F & Serum Albumin Reference Antibody (Sonelokimab) is 98.70%, determined by SEC-HPLC.


Sonelokimab bound to IL-17F protein, and then rebounded to secondary antibodies (Anti-human-IgG-His-HRP), and read OD450. As shown in fig, Sonelokimab bound in hu-IL-17F-Fc, and the EC50 was




0.009 nM.



Sonelokimab bound to HSA protein, and then rebounded to secondary antibodies (Anti-human-IgG-His-HRP) , and read OD450. As shown in fig, Sonelokimab bound in hu-HSA-Fc, and the EC50 was 0.022nM.



Co-incubation of NHDF cells with TNF-α and IL-17A protein, then with the addition of Sonelokimab and incubated for 24 hours. IL-6 was measured by ELISA. As shown in fig 3, Sonelokimab can neutralize IL17-A-induced IL-6 factor secretion, and the IC50 was 2.877 nM.



The detected molecular weight of Anti-IL-17 & IL-17F & Serum Albumin Reference Antibody (Sonelokimab) is 40.93 kDa.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.